{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:51:55Z","timestamp":1791168715919,"version":"4.1.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar Research Development and Innovation Council","award":["ARG02-0402-240119"],"award-info":[{"award-number":["ARG02-0402-240119"]}]},{"name":"Qatar Research Development and Innovation Council"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%\u20136.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%\u20139.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%\u201353.2%). The rVE was 26.9% (95% CI, \u221212.7%\u201353.4%) within &amp;lt;24 days, 51.8% (95% CI, 19.2%\u201371.2%) during Days 24\u2013179, and 36.8% (95% CI, 0.9%\u201359.7%) at \u2265180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag602","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:21:51Z","timestamp":1789672911000},"source":"Crossref","is-referenced-by-count":0,"title":["Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-6968","authenticated-orcid":false,"given":"Hiam","family":"Chemaitelly","sequence":"first","affiliation":[{"name":"Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University , Doha ,","place":["Qatar"]},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-6657","authenticated-orcid":false,"given":"Houssein H","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Mathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0819-6103","authenticated-orcid":false,"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]},{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University , Doha ,","place":["Qatar"]},{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queens University , Belfast ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-5484","authenticated-orcid":false,"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7949","authenticated-orcid":false,"given":"Mohammad R","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-2788","authenticated-orcid":false,"given":"Hadi M","family":"Yassine","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University , Doha ,","place":["Qatar"]},{"name":"Biomedical Research Center, QU Health, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2715-3712","authenticated-orcid":false,"given":"Asmaa A","family":"Al Thani","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University , Doha ,","place":["Qatar"]},{"name":"Biomedical Research Center, QU Health, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-4255","authenticated-orcid":false,"given":"Zaina","family":"Al-Kanaani","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-2334","authenticated-orcid":false,"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-2713","authenticated-orcid":false,"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-4750","authenticated-orcid":false,"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9011-4391","authenticated-orcid":false,"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-5854","authenticated-orcid":false,"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-5142","authenticated-orcid":false,"given":"Hanan F","family":"Abdul-Rahim","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Health Sciences, QU Health, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1038","authenticated-orcid":false,"given":"Gheyath K","family":"Nasrallah","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University , Doha ,","place":["Qatar"]},{"name":"Biomedical Research Center, QU Health, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-5395","authenticated-orcid":false,"given":"Mohamed Ghaith","family":"Al-Kuwari","sequence":"additional","affiliation":[{"name":"Primary Health Care Corporation , Doha ,","place":["Qatar"]},{"name":"College of Medicine, Qatar University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-1826","authenticated-orcid":false,"given":"Adeel A","family":"Butt","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University , New York, New York ,","place":["USA"]},{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]},{"name":"Department of Medicine, Weill Cornell Medicine, Cornell University , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-8499","authenticated-orcid":false,"given":"Hamad Eid","family":"Al-Romaihi","sequence":"additional","affiliation":[{"name":"Ministry of Public Health , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-6941","authenticated-orcid":false,"given":"Mohamed H","family":"Al-Thani","sequence":"additional","affiliation":[{"name":"Ministry of Public Health , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-8253","authenticated-orcid":false,"given":"Abdullatif","family":"Al-Khal","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J","family":"Abu-Raddad","sequence":"additional","affiliation":[{"name":"Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University , Doha ,","place":["Qatar"]},{"name":"Department of Population Health Sciences, Weill Cornell Medicine, Cornell University , New York, New York ,","place":["USA"]},{"name":"Biomedical Research Center, QU Health, Qatar University , Doha ,","place":["Qatar"]},{"name":"College of Health and Life Sciences, Hamad bin Khalifa University , Doha ,","place":["Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026100422265460500_ofag602-B1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Roltgen","year":"2022","journal-title":"Cell"},{"key":"2026100422265460500_ofag602-B2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.abm0811","article-title":"Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants","volume":"375","author":"Reynolds","year":"2022","journal-title":"Science"},{"key":"2026100422265460500_ofag602-B3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"key":"2026100422265460500_ofag602-B4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh0761","article-title":"History of primary-series and booster vaccination and protection against omicron reinfection","volume":"9","author":"Chemaitelly","year":"2023","journal-title":"Sci Adv"},{"key":"2026100422265460500_ofag602-B5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMc2211055","article-title":"Immune imprinting and protection against repeat reinfection with SARS-CoV-2","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41586-024-08511-9","article-title":"Differential protection against SARS-CoV-2 reinfection pre- and post-omicron","volume":"639","author":"Chemaitelly","year":"2025","journal-title":"Nature"},{"key":"2026100422265460500_ofag602-B7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","article-title":"Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026100422265460500_ofag602-B8","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.vaccine.2015.07.062","article-title":"Methodological challenges in measuring vaccine effectiveness using population cohorts in low resource settings","volume":"33","author":"King","year":"2015","journal-title":"Vaccine"},{"key":"2026100422265460500_ofag602-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol Rev"},{"key":"2026100422265460500_ofag602-B10","article-title":"Delaying the second dose of covid-19 vaccines","volume":"372","author":"Pimenta","year":"2021","journal-title":"BMJ"},{"key":"2026100422265460500_ofag602-B11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41590-022-01143-z","article-title":"A potential silver lining of delaying the second dose","volume":"23","author":"Martinez","year":"2022","journal-title":"Nat Immunol"},{"key":"2026100422265460500_ofag602-B12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/infdis\/jiac023","article-title":"Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against severe acute respiratory syndrome coronavirus 2, including variants of concern: test-negative design, British Columbia, Canada","volume":"226","author":"Skowronski","year":"2022","journal-title":"J Infect Dis"},{"key":"2026100422265460500_ofag602-B13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B14","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2026100422265460500_ofag602-B16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/medethics-2021-107956","article-title":"The unnaturalistic fallacy: COVID-19 vaccine mandates should not discriminate against natural immunity","volume":"48","author":"Pugh","year":"2022","journal-title":"J Med Ethics"},{"key":"2026100422265460500_ofag602-B17","doi-asserted-by":"publisher","author":"Geddes","DOI":"10.1056\/NEJMc2101667"},{"key":"2026100422265460500_ofag602-B18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc2119432","article-title":"Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMc2117933","article-title":"Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B23","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad106","article-title":"Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections","volume":"30","author":"Chemaitelly","year":"2023","journal-title":"J Travel Med"},{"key":"2026100422265460500_ofag602-B24","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1038\/s41598-021-85428-7","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"11","author":"Abu-Raddad","year":"2021","journal-title":"Sci Rep"},{"key":"2026100422265460500_ofag602-B25","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012291","article-title":"All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic","volume":"8","author":"AlNuaimi","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2026100422265460500_ofag602-B27","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.2021.19623","article-title":"Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar","volume":"326","author":"Abu-Raddad","year":"2021","journal-title":"JAMA"},{"key":"2026100422265460500_ofag602-B28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa2210058","article-title":"Covid-19 vaccine protection among children and adolescents in Qatar","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B29","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1016\/S2666-5247(22)00287-7","article-title":"Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study","volume":"3","author":"Chemaitelly","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026100422265460500_ofag602-B30","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13224","article-title":"SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: a national cohort study","volume":"17","author":"Mahmoud","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"2026100422265460500_ofag602-B31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.103690","article-title":"Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar","volume":"14","author":"Chemaitelly","year":"2025","journal-title":"Elife"},{"key":"2026100422265460500_ofag602-B32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1473-3099(23)00005-1","article-title":"BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents","volume":"23","author":"Chemaitelly","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026100422265460500_ofag602-B33","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13357","article-title":"BNT162b2 versus mRNA-1273 vaccines: comparative analysis of long-term protection against SARS-CoV-2 infection and severe COVID-19 in Qatar","volume":"18","author":"Chemaitelly","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2026100422265460500_ofag602-B34","doi-asserted-by":"crossref","first-page":"35179","DOI":"10.1038\/s41598-025-19168-3","article-title":"Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar","volume":"15","author":"Sukik","year":"2025","journal-title":"Sci Rep"},{"key":"2026100422265460500_ofag602-B35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijid.2023.09.005","article-title":"Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study","volume":"136","author":"Chemaitelly","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026100422265460500_ofag602-B36","author":"World Health Organization (WHO)"},{"key":"2026100422265460500_ofag602-B37","author":"World Health Organization (WHO)"},{"key":"2026100422265460500_ofag602-B38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2023-000479","article-title":"Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar","volume":"1","author":"Chemaitelly","year":"2023","journal-title":"BMJ Public Health"},{"key":"2026100422265460500_ofag602-B39","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf098","article-title":"Evaluating hospital admission data as indicators of COVID-19 severity: a national assessment in Qatar","volume":"12","author":"Sukik","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026100422265460500_ofag602-B40","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"key":"2026100422265460500_ofag602-B41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/01632787211047932","article-title":"A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection","volume":"44","author":"Kojima","year":"2021","journal-title":"Eval Health Prof"},{"key":"2026100422265460500_ofag602-B42","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1363045","article-title":"Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation","volume":"11","author":"Chemaitelly","year":"2024","journal-title":"Front Med"},{"key":"2026100422265460500_ofag602-B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102646","article-title":"SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals","volume":"24","author":"Coyle","year":"2021","journal-title":"iScience"},{"key":"2026100422265460500_ofag602-B44","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3201\/eid2705.204365","article-title":"Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar","volume":"27","author":"Jeremijenko","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026100422265460500_ofag602-B45","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab221","article-title":"SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar","volume":"8","author":"Al-Thani","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026100422265460500_ofag602-B46","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"2026100422265460500_ofag602-B47","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"2026100422265460500_ofag602-B48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2026100422265460500_ofag602-B49","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1002\/sim.5879","article-title":"Ignoring the matching variables in cohort studies - when is it valid and why?","volume":"32","author":"Sjolander","year":"2013","journal-title":"Stat Med"},{"key":"2026100422265460500_ofag602-B50","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"2026100422265460500_ofag602-B51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41467-023-35815-7","article-title":"Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat Commun"},{"key":"2026100422265460500_ofag602-B52","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMc2108120","article-title":"Severity of SARS-CoV-2 reinfections as compared with primary infections","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B53","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection","volume":"29","author":"Chemaitelly","year":"2022","journal-title":"J Travel Med"},{"key":"2026100422265460500_ofag602-B54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104734","article-title":"Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study","volume":"95","author":"Altarawneh","year":"2023","journal-title":"EBioMedicine"},{"key":"2026100422265460500_ofag602-B55","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026100422265460500_ofag602-B56","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained\u2014a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100422265460500_ofag602-B57","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127556","article-title":"Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: evidence of converging protection over time","volume":"62","author":"Chemaitelly","year":"2025","journal-title":"Vaccine"},{"key":"2026100422265460500_ofag602-B58","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people?","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2026100422265460500_ofag602-B59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"2026100422265460500_ofag602-B60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cger.2022.03.003","article-title":"Inflammaging at the time of COVID-19","volume":"38","author":"Zazzara","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"2026100422265460500_ofag602-B61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271324","article-title":"COVID-19 risk score as a public health tool to guide targeted testing: a demonstration study in Qatar","volume":"17","author":"Abu-Raddad","year":"2022","journal-title":"PLoS One"},{"key":"2026100422265460500_ofag602-B62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijid.2023.03.022","article-title":"Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies","volume":"131","author":"Bodner","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026100422265460500_ofag602-B63","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"key":"2026100422265460500_ofag602-B64","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.05005","article-title":"Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19","volume":"11","author":"Ayoub","year":"2021","journal-title":"J Glob Health"},{"key":"2026100422265460500_ofag602-B65","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab083","article-title":"Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses","volume":"28","author":"Abu-Raddad","year":"2021","journal-title":"J Travel Med"},{"key":"2026100422265460500_ofag602-B66","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag602\/71303558\/ofag602.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag602\/71303558\/ofag602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag602\/71303558\/ofag602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:27:07Z","timestamp":1791167227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag602\/8826564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag602","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,22]]},"article-number":"ofag602"}}